<DOC>
	<DOC>NCT00699049</DOC>
	<brief_summary>The purpose of this study is to explore additional benefit of solifenacin after 12-week treatment, compared with alpha blocker monotherapy in men with residual OAB symptoms.</brief_summary>
	<brief_title>A Study Comparing the Efficacy of an Alpha Blocker Versus an Alpha Blocker Plus Solifenacin in Men With Overactive Bladder</brief_title>
	<detailed_description />
	<mesh_term>Urinary Bladder, Overactive</mesh_term>
	<mesh_term>Solifenacin Succinate</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Persistent symptoms of OAB as verified by the 3 day voiding diary, defined by: symptoms of urinary urgency (defined as a level of &gt;=3 in a 5 point urgency scale) at least two episode per 24 hours and symptoms of urinary frequency ( &gt;8 micturitions per 24 hours) On a stable dose of tamsulosin for at least 1 month Previous history of acute urinary retention Patients have a baseline postvoid residual (PVR) which exceeded 50% of voided urine volume Any condition that is a contraindication for anticholinergic treatment, including uncontrolled narrowangled glaucoma, urinary retention or gastric retention Symptomatic acute urinary tract infection (UTI) during the screening period Treatment within the 14 days preceding randomization, or expected to initiate treatment during the study with any anticholinergic drugs and drug treatment for overactive bladder A 5alpha reductase inhibitor if started less than 3 months prior to screening Patients with previous urethral, prostate or bladder neck surgery</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Alpha blocker</keyword>
	<keyword>Tamsulosin</keyword>
	<keyword>Solifenacin</keyword>
	<keyword>Overactive Bladder</keyword>
	<keyword>Urgency incontinence</keyword>
</DOC>